Arcturus Therapeutics Holdings ARCT
NASDAQ ARCT
$15.82 +0.26 (+1.67%)
As of: Sep 4, 2026 · 3:59 PM EDT

Arcturus Therapeutics Holdings (ARCT) Total Current Liabilities (2018 - 2026)

Arcturus Therapeutics Holdings' (ARCT) quarterly Total Current Liabilities came in at $34.4 million in Q1 2026, down 30.44% YoY from $49.4 million in Q1 2025, and down 5.53% on a QoQ basis from $36.4 million in Q4 2025.

Analysis

Arcturus Therapeutics Holdings (ARCT) Total Current Liabilities (2018 - 2026) Analysis & Trends

Arcturus Therapeutics Holdings (ARCT) has 9 years of Total Current Liabilities data on file, last reported at $34.4 million in Q1 2026.

  • Quarterly Total Current Liabilities fell 30.44% year-over-year to $34.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.4 million (down 30.44% YoY) and the FY2025 annual result came in at $36.4 million, down 44.45% from the prior year.
  • Total Current Liabilities declined to $34.4 million in Q1 2026, from $36.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $127.0 million in Q4 2022 to a low of $31.7 million in Q3 2025.
  • A 5-year average of $76.1 million and a median of $82.0 million in 2023 frame the typical range for Total Current Liabilities.
  • Annual changes were most pronounced in 2022 — Total Current Liabilities soared 101.2% — and 2025, when it slumped 57.2%.
  • Tracing ARCT's Total Current Liabilities over 5 years: stood at $127.0 million in 2022, then sank by 35.43% to $82.0 million in 2023, then slipped by 20.12% to $65.5 million in 2024, then plunged by 44.45% to $36.4 million in 2025, then fell by 5.53% to $34.4 million in 2026.
  • The last three Total Current Liabilities figures came in at $34.4 million (Q1 2026), $36.4 million (Q4 2025), and $31.7 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 3.94 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 5.53 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.58 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 2.53 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 354.06 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 2.12 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 1.51 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 630.93 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 438.74 Mn
10 Arcturus Therapeutics Holdings 449.65 Mn 258.17 Mn - 33.54 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 33.54 Mn
Mar 31, 2026 34.37 Mn
Dec 31, 2025 36.38 Mn
Sep 30, 2025 31.70 Mn
Jun 30, 2025 46.52 Mn
Mar 31, 2025 49.41 Mn
Dec 31, 2024 65.49 Mn
Sep 30, 2024 69.46 Mn
Jun 30, 2024 91.72 Mn
Mar 31, 2024 115.43 Mn
Dec 31, 2023 81.99 Mn
Sep 30, 2023 87.68 Mn
Jun 30, 2023 90.35 Mn
Mar 31, 2023 90.13 Mn
Dec 31, 2022 126.98 Mn
Sep 30, 2022 75.85 Mn
Jun 30, 2022 92.74 Mn
Mar 31, 2022 107.31 Mn
Dec 31, 2021 99.54 Mn
Sep 30, 2021 118.24 Mn